Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Breast Neoplasms 291Carcinoma, Non-Small-Cell Lung 222Neoplasms 193Prostatic Neoplasms 158Multiple Myeloma 138Neoplasm Metastasis 115Melanoma 110Colorectal Neoplasms 107Leukemia, Myeloid, Acute 103Lymphoma 97Lung Neoplasms 94Ovarian Neoplasms 84Squamous Cell Carcinoma of Head and Neck 75Lymphoma, Non-Hodgkin 73Leukemia, Lymphocytic, Chronic, B-Cell 70Pancreatic Neoplasms 64Triple Negative Breast Neoplasms 62Myelodysplastic Syndromes 62Parkinson Disease 4, Autosomal Dominant Lewy Body 59Hematologic Neoplasms 59Head and Neck Neoplasms 59Recurrence 56Glioblastoma 55Leukemia 53Precursor Cell Lymphoblastic Leukemia-Lymphoma 52Sarcoma 49Brain Neoplasms 49Lymphoma, Large B-Cell, Diffuse 47Carcinoma, Hepatocellular 47Lymphoma, Follicular 45

Interventions

patritumab deruxtecan 1durvalumab 1Pemetrexed 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Non-Small Cell Lung Cancer Metastatic × 1 year × Clear all
NCT04163432 2026-05-19

STAGGER

University of Utah

Phase 2 Active not recruiting
43 enrolled 12 charts
Thoracic

Non-Small Cell Lung Cancer Metastatic

NCT04619004 2026-05-14

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

Daiichi Sankyo

Phase 2 Active not recruiting
277 enrolled 16 charts
Thoracic

Non-Small Cell Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡